The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth

• Published in: Animal cells and systems Vol. 28; no. 1; pp. 93 - 109
• Main Authors: Kim, Hyun-Jin, Batara, Don Carlo, Jeon, Young-Jun, Lee, Seongsoo, Beck, Samuel, Kim, Sung-Hak
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 31.12.2024; Taylor & Francis Ltd; Taylor & Francis Group; 한국통합생물학회
• Subjects: Animal sciences; animals; Biochemistry; Biomarkers; Brain cancer; Cell cycle; Cell differentiation; Cell growth; Data analysis; data collection; Dermatology; Esophagus; Genes; glioblastoma; Glioma; Glioma cells; glioma stem cell; Growth factors; Hematopoiesis; Hemopoiesis; Homeobox; Laboratories; Leukemia; Life sciences; MEIS1; Prostate; Proteins; RNA polymerase; Stem cells; therapeutics; Transcription factors; Transcriptomics; viruses; Zoology; 생물학; MEIS1; glioblastoma; glioma stem cell
• ISSN: 1976-8354; 2151-2485; 2151-2485
• DOI: 10.1080/19768354.2024.2327340

Myeloid ecotropic virus insertion site 1 (MEIS1) is a HOX co-factor necessary for organ development and normal hematopoiesis. Recently, MEIS1 has been linked to the development and progression of various cancers. However, its role in gliomagenesis particularly on glioma stem cells (GSCs) remains unclear. Here, we demonstrate that MEIS1 is highly upregulated in GSCs compared to normal, and glioma cells and to its differentiated counterparts. Inhibition of MEIS1 expression by shRNA significantly reduced GSC growth in both in vitro and in vivo experiments. On the other hand, integrated transcriptomics analyses of glioma datasets revealed that MEIS1 expression is correlated to cell cycle-related genes. Clinical data analysis revealed that MEIS1 expression is elevated in high-grade gliomas, and patients with high MEIS1 levels have poorer overall survival outcomes. The findings suggest that MEIS1 is a prognostic biomarker for glioma patients and a possible target for developing novel therapeutic strategies against GBM.